Full Press Release Details
• World’s first Phase 3 readout for anin vivoCRISPR gene editing candidate
• Company to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026
CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) --Intellia Therapeutics, Inc.(Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data.
To join the webcast, please visit the Events page of the Investors & Media section on Intellia’s website atintelliatx.com. A replay of the webcast will be available for approximately 90 days.
About Intellia TherapeuticsIntellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more atintelliatx.comand follow us@intelliatx.
Investor Contact:Jason FredetteVice President, Investor Relations and Corporate CommunicationsIntellia Therapeutics, Inc.jason.fredette@intelliatx.com